4.1.22 WCHD Provider Advisory~ COVID Therapeutics

Requested Actions

  • Be aware, the Centers for Disease Control and Prevention (CDC) and Western States Scientific Safety Review Workgroup have endorsed the Food and Drug Administration (FDA) emergency use authorization of a second booster dose of either the Pfizer-BioNTech (Pfizer) or Moderna COVID-19 vaccines for specific groups. These second boosters are particularly important for people over 65 and for people over 50 with certain underlying medical conditions. These changes now allow:
    • A second booster dose of the Pfizer COVID-19 vaccine for everyone 50 and older and for people 12 and older who are immune compromised at least 4 months after their first booster dose.
    • A second booster dose of Moderna COVID-19 vaccine for everyone 50 and older and people 18 and older who are immune compromised at least 4 months after their first booster dose.
    • Following newly published data, a second booster dose of either Pfizer or Moderna COVID-19 vaccine at least 4 months after the primary and first booster dose of Johnson & Johnson COVID-19 vaccine for people 18 years or older.

 

 

 

COVID-19 vaccine information

COVID-19 testing

 COVID-19 therapies

Department of Health and Human Services (HHS) allocates monoclonal antibodies and oral antivirals to each state. DOH distributes doses to enrolled providers. Providers must enroll in Healthcare Partner Ordering Portal (HPoP) to manage COVID-19 therapies. Email mcm@doh.wa.gov for support enrolling.

Once enrolled, to request a supply of monoclonal antibodies or therapeutics, complete a smart sheet.

Supplies of all therapies are widely available.  Commercial and independent pharmacies may have oral antivirals. Hospital-associated systems may have monoclonal antibodies. All therapies must be dispensed by prescription. Therapies from pharmacies may be intended for home delivery. Patients with questions about accessing their medication should call the pharmacy.

Washington is among the states where as of March 29, 2022 the CDC estimates that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is above 50%. For this reason, Sotrovimab is not authorized at this time for use in Washington State.

Infusion Solutions will now offer only Bebtelovimab as a treatment for COVID-19.  Please use Infusion Solutions new order form if you determine that Bebtelovimab is appropriate for your patients. Please note, it is now recommended to be given within 7 days of symptom onset, instead of 10 days with the previously authorized COVID treatment mAbs.

Centers for Disease Control and Prevention (CDC) Nowcast data.

https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization

Additional information

 COVID-19 prevention

Share with patients:

 Contacting the Health Department

360-778-6100        Main Call Line – available M-F 8:30am to 4:30pm

360-715-2588        Afterhours Answering Service – available after 4:30pm and weekends

360-778-6150        Communicable Disease Report Line – 24 hours a day 7 days a week

360-778-6103        Confidential Communicable Disease Fax – 24 hours a day 7 days a week

1500 N State Street, Bellingham WA 98225